Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Amlodipine / Valsartan

Pronunciation: am-LOE-di-peen/val-SAR-tan
Class: Antihypertensive combination

Trade Names

- Tablets, oral amlodipine 5 mg/valsartan 160 mg
- Tablets, oral amlodipine 10 mg/valsartan 160 mg
- Tablets, oral amlodipine 5 mg/valsartan 320 mg
- Tablets, oral amlodipine 10 mg/valsartan 320 mg



Inhibits movement of calcium ions across cell membranes in systemic and coronary vascular smooth muscle.


Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor in vascular smooth muscle and the adrenal gland, producing decreased BP.

Indications and Usage

For the treatment of hypertension.


None well documented.

Dosage and Administration


PO Amlodipine 5 mg/valsartan 160 mg once daily initially. May increase after 1 to 2 wk to a maximum dosage of amlodipine 10 mg/valsartan 320 mg once daily.


PO Initially, amlodipine 2.5 mg once daily. Because this is a fixed-dose combination tablet, therapy with amlodipine/valsartan may not be appropriate initial therapy in elderly patients.

Renal Function Impairment

PO Titrate slowly.

Hepatic Function Impairment

PO Initially, amlodipine 2.5 mg once daily. Because this is a fixed-dose combination tablet, therapy with amlodipine/valsartan may not be appropriate initial therapy in patients with hepatic impairment; titrate slowly.

General Advice

  • May be taken with or without food.
  • May be administered with other antihypertensive agents.
  • Patients not adequately controlled on amlodipine (or another dihydropyridine calcium channel blocker) alone or valsartan (or another angiotensin II receptor blocker) alone may be switched to amlodipine/valsartan.
  • May be substituted for individually titrated components.
  • Not indicated for initial therapy in volume-depleted patients.


Store between 59° and 86°F; protect from moisture.

Drug Interactions

No drug interaction studies have been conducted with amlodipine/valsartan. The following interactions are based on drug interactions involving each component of the amlodipine/valsartan combination.

ACE inhibitors (eg, captopril)

Coadministration may increase the risk of hyperkalemia and renal dysfunction. Consider monotherapy. If coadministration cannot be avoided, closely monitor renal function and serum potassium.


The risk of hyperkalemia may be increased with coadministration, especially in diabetic patients. Furthermore, addition of aliskiren to amlodipine/valsartan in diabetic patients may increase the risk of nonfatal stroke, renal complications, and hypotension. Coadministration is not recommended in diabetic patients.

Azole antifungal agents (eg, itraconazole, ketoconazole)

Azole antifungals may increase the plasma concentrations and pharmacologic effects of amlodipine. If an interaction is suspected, consider decreasing the dosage.


Plasma concentrations of amlodipine may be increased. Clinical monitoring for signs of an extended pharmacologic effect of amlodipine is warranted.

Cyclooxygenase 2 inhibitors (eg, celecoxib), NSAIDs (eg, ibuprofen, indomethacin)

Coadministration may result in deterioration of renal function, including acute renal failure, especially in patients with renal impairment, those who are volume depleted, or elderly patients. In addition, the antihypertensive effect of valsartan may be reduced by NSAIDs. Monitor renal function and BP.

Drugs that increase potassium concentrations (eg, potassium supplements, salt substitutes)

Serum potassium concentrations may be increased. Closely monitor serum potassium. Adjust treatment as needed.


Lithium plasma concentrations may be elevated, increasing its pharmacologic effects. Monitor lithium levels; adjust dose accordingly.

Potassium-sparing diuretics (eg, amiloride)

The risk of hyperkalemia may be increased, especially in high-risk patients (eg, renal impairment, type 2 diabetes). Closely monitor serum potassium and renal function. Adjust therapy as needed.

Protease inhibitors (eg, indinavir, ritonavir)

The antihypertensive effects of amlodipine may be increased. Use with caution and monitor clinical response. Reduce dosage as needed.


Coadministration resulted in increased BP-lowering effect. Monitor BP.


Plasma concentrations and pharmacologic effects of simvastatin may be increased. The daily dose of simvastatin should not exceed 20 mg when amlodipine is coadministered.


The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter organic anion–transporting polypeptide OATP1B1 and the hepatic efflux transporter multidrug resistance protein 2. Coadministration of inhibitors of the uptake transporter (cyclosporine, rifampin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.


The risk of hyperkalemia is increased, especially in elderly patients. Monitor serum potassium concentrations and clinical response. Consider alternative antibiotic treatment. Adjust the antihypertensive dose as needed.

Adverse Reactions


Hypotension (6%); vasculitis (postmarketing).


Increased BUN (6%); increased creatinine (4%); gynecomastia, renal impairment (postmarketing).


Elevated liver enzymes, hepatitis, jaundice (postmarketing).


Peripheral edema (5%); hyperkalemia (3%).


Nasopharyngitis (4%); cough, upper respiratory tract infection (3%).


Dizziness (2%); alopecia, angioedema, rhabdomyolysis, thrombocytopenia (postmarketing).



When pregnancy is detected, discontinue therapy as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.


Correct volume and/or salt depletion before initiating therapy. Evaluate renal function and measure serum electrolytes before starting therapy and periodically thereafter. Monitor BP and pulse on a regular basis.


Category D . Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue therapy as soon as possible.


Undetermined. Breast-feeding is not recommended.


Safety and efficacy not established.


Use with caution.

Renal Function

In studies of ACE inhibitors in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or BUN may occur. Valsartan would be expected to behave similarly.

Hepatic Function

Use with caution.

Special Risk Patients

Initiate therapy cautiously in patients with heart failure, recent MI, or severe aortic stenosis, and in patients undergoing surgery or dialysis.

Cardiovascular effects

Increased frequency, duration, or severity of angina or acute MI may occur. Use with caution in patients with heart failure or severe aortic stenosis.


May occur.


Decreases in BP may occur, especially in salt- or volume-depleted patients. Volume and salt depletion should be corrected before initiating therapy.

Renal effects

Changes in renal function may occur, especially in volume-depleted patients. Oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death may occur in patients whose renal function may depend on the activity of renin-angiotensin-aldosterone system (eg, patients with severe CHF).



Bradycardia, circulatory collapse, depressed consciousness, hypotension, peripheral vasodilation, shock, tachycardia.

Patient Information

  • Inform women of childbearing age about the consequences of exposure to drugs that act on the renin-angiotensin system. Discuss other treatment options with women planning to become pregnant. Ask these patients to report pregnancies to their health care provider as soon as possible.
  • Caution patients that light-headedness can occur, especially during the first few days of therapy, and that it should be reported to their prescribing health care provider. Inform patients that if syncope occurs, therapy should be discontinued until the health care provider has been consulted.
  • Caution patients that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in BP, light-headedness, and possible syncope.
  • Advise patients not to take potassium supplements or salt substitutes containing potassium without consulting their health care provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.